JP2018524331A5 - - Google Patents

Download PDF

Info

Publication number: JP2018524331A5
Authority: JP; Japan
Prior art keywords: pyridin; alkyl; carbonitrile; compound; imidazo
Prior art date: 2016-06-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2017566812A

Other languages

English (en)

Japanese (ja)

Other versions

JP2018524331A (ja

JP6720225B2 (ja

Filing date

2016-06-23

Publication date

2019-07-18

2016-06-23 Application filed filed Critical

2016-06-23 Priority claimed from PCT/US2016/038862 external-priority patent/WO2016210037A1/en

2018-08-30 Publication of JP2018524331A publication Critical patent/JP2018524331A/ja

2019-07-18 Publication of JP2018524331A5 publication Critical patent/JP2018524331A5/ja

2020-07-08 Application granted granted Critical

2020-07-08 Publication of JP6720225B2 publication Critical patent/JP6720225B2/ja

Status Active legal-status Critical Current

2036-06-23 Anticipated expiration legal-status Critical

Links

-1 imidazo [1,2-b] pyridazinyl Chemical group 0.000 claims 37
150000001875 compounds Chemical class 0.000 claims 20
125000000217 alkyl group Chemical group 0.000 claims 16
OAQFIXDKTZYDRL-UHFFFAOYSA-N imidazo[1,2-b]pyridazine-7-carbonitrile Chemical compound N=1C=CN2N=CC(=CC2=1)C#N OAQFIXDKTZYDRL-UHFFFAOYSA-N 0.000 claims 14
125000001072 heteroaryl group Chemical group 0.000 claims 13
150000003839 salts Chemical class 0.000 claims 12
125000004093 cyano group Chemical group *C#N 0.000 claims 9
125000001412 tetrahydropyranyl group Chemical group 0.000 claims 9
125000003226 pyrazolyl group Chemical group 0.000 claims 8
125000004076 pyridyl group Chemical group 0.000 claims 8
125000003566 oxetanyl group Chemical group 0.000 claims 7
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
125000003709 fluoroalkyl group Chemical group 0.000 claims 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
239000008194 pharmaceutical composition Substances 0.000 claims 5
125000001425 triazolyl group Chemical group 0.000 claims 5
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 4
229910052799 carbon Inorganic materials 0.000 claims 4
125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
125000002883 imidazolyl group Chemical group 0.000 claims 4
CAJZIMCVNPNPSW-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-6-carbonitrile Chemical compound C1=C(C#N)C=NC2=CC=NN21 CAJZIMCVNPNPSW-UHFFFAOYSA-N 0.000 claims 4
ZIEWSZYVEDTXGH-UHFFFAOYSA-N pyrimidine-4-carbonitrile Chemical compound N#CC1=CC=NC=N1 ZIEWSZYVEDTXGH-UHFFFAOYSA-N 0.000 claims 4
125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 4
125000001424 substituent group Chemical group 0.000 claims 3
238000002560 therapeutic procedure Methods 0.000 claims 3
DOTOFFAVTNZRLB-UHFFFAOYSA-N 2-(7-chloroimidazo[1,2-b]pyridazin-3-yl)-N-cyclopropyl-5-(1-propyltriazol-4-yl)pyridin-4-amine Chemical compound ClC1=CC=2N(N=C1)C(=CN=2)C1=NC=C(C(=C1)NC1CC1)C=1N=NN(C=1)CCC DOTOFFAVTNZRLB-UHFFFAOYSA-N 0.000 claims 2
ZBRIPMUNBFXCSD-UHFFFAOYSA-N 2-(7-chloroimidazo[1,2-b]pyridazin-3-yl)-N-propan-2-yl-5-(1-propyltriazol-4-yl)pyridin-4-amine Chemical compound ClC1=CC=2N(N=C1)C(=CN=2)C1=NC=C(C(=C1)NC(C)C)C=1N=NN(C=1)CCC ZBRIPMUNBFXCSD-UHFFFAOYSA-N 0.000 claims 2
KFILYRVIDVXHNI-UHFFFAOYSA-N 2-(7-chloroimidazo[1,2-b]pyridazin-3-yl)-N-propan-2-yl-5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyridin-4-amine Chemical compound ClC1=CC=2N(N=C1)C(=CN=2)C1=NC=C(C(=C1)NC(C)C)C=1C=NN(C=1)CC(F)(F)F KFILYRVIDVXHNI-UHFFFAOYSA-N 0.000 claims 2
JDHXZJLBUNAELN-UHFFFAOYSA-N 3-[4-(cyclopropylamino)-5-(1-propyltriazol-4-yl)pyridin-2-yl]imidazo[1,2-b]pyridazine-7-carbonitrile Chemical compound C1(CC1)NC1=CC(=NC=C1C=1N=NN(C=1)CCC)C1=CN=C2N1N=CC(=C2)C#N JDHXZJLBUNAELN-UHFFFAOYSA-N 0.000 claims 2
FRYFNOMIOVBKEM-UHFFFAOYSA-N 3-[4-[(3,3-difluorocyclobutyl)amino]-5-[4-(3-hydroxy-3-methylbutyl)triazol-1-yl]pyridin-2-yl]pyrazolo[1,5-a]pyrimidine-6-carbonitrile Chemical compound FC1(CC(C1)NC1=CC(=NC=C1N1N=NC(=C1)CCC(C)(C)O)C=1C=NN2C=1N=CC(=C2)C#N)F FRYFNOMIOVBKEM-UHFFFAOYSA-N 0.000 claims 2
FXJWDSCIKROGLP-UHFFFAOYSA-N 3-[5-[1-(1-acetylazetidin-3-yl)triazol-4-yl]-4-(propan-2-ylamino)pyridin-2-yl]imidazo[1,2-b]pyridazine-7-carbonitrile Chemical compound C(C)(=O)N1CC(C1)N1N=NC(=C1)C=1C(=CC(=NC=1)C1=CN=C2N1N=CC(=C2)C#N)NC(C)C FXJWDSCIKROGLP-UHFFFAOYSA-N 0.000 claims 2
XOYXADDAQJVPEI-UHFFFAOYSA-N 3-[5-[1-(3-hydroxy-3-methylbutyl)pyrazol-4-yl]-4-(propan-2-ylamino)pyridin-2-yl]imidazo[1,2-b]pyridazine-7-carbonitrile Chemical compound OC(CCN1N=CC(=C1)C=1C(=CC(=NC=1)C1=CN=C2N1N=CC(=C2)C#N)NC(C)C)(C)C XOYXADDAQJVPEI-UHFFFAOYSA-N 0.000 claims 2
PYJGADHQKPQSHH-UHFFFAOYSA-N 3-[5-[4-(3-hydroxy-3-methylbutyl)triazol-1-yl]-4-(oxetan-3-ylamino)pyridin-2-yl]pyrazolo[1,5-a]pyrimidine-6-carbonitrile Chemical compound OC(CCC=1N=NN(C=1)C=1C(=CC(=NC=1)C=1C=NN2C=1N=CC(=C2)C#N)NC1COC1)(C)C PYJGADHQKPQSHH-UHFFFAOYSA-N 0.000 claims 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
201000005569 Gout Diseases 0.000 claims 2
125000002393 azetidinyl group Chemical group 0.000 claims 2
125000004966 cyanoalkyl group Chemical group 0.000 claims 2
229960004979 fampridine Drugs 0.000 claims 2
206010025135 lupus erythematosus Diseases 0.000 claims 2
125000002757 morpholinyl group Chemical group 0.000 claims 2
230000000737 periodic effect Effects 0.000 claims 2
125000004193 piperazinyl group Chemical group 0.000 claims 2
125000003386 piperidinyl group Chemical group 0.000 claims 2
125000000714 pyrimidinyl group Chemical group 0.000 claims 2
125000000168 pyrrolyl group Chemical group 0.000 claims 2
208000011580 syndromic disease Diseases 0.000 claims 2
125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
WAGVYTPQQZVQJF-UHFFFAOYSA-N 1-(oxan-4-yl)pyrazole Chemical compound C1COCCC1N1N=CC=C1 WAGVYTPQQZVQJF-UHFFFAOYSA-N 0.000 claims 1
FLCAFSOTMLXPPX-UHFFFAOYSA-N 7-chloroimidazo[1,2-b]pyridazine Chemical compound C1=C(Cl)C=NN2C=CN=C21 FLCAFSOTMLXPPX-UHFFFAOYSA-N 0.000 claims 1
208000026326 Adult-onset Still disease Diseases 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
208000023328 Basedow disease Diseases 0.000 claims 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
206010009900 Colitis ulcerative Diseases 0.000 claims 1
208000011231 Crohn disease Diseases 0.000 claims 1
206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
206010018634 Gouty Arthritis Diseases 0.000 claims 1
208000009329 Graft vs Host Disease Diseases 0.000 claims 1
208000015023 Graves' disease Diseases 0.000 claims 1
235000010650 Hyssopus officinalis Nutrition 0.000 claims 1
240000001812 Hyssopus officinalis Species 0.000 claims 1
208000003456 Juvenile Arthritis Diseases 0.000 claims 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
208000005777 Lupus Nephritis Diseases 0.000 claims 1
102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
201000006704 Ulcerative Colitis Diseases 0.000 claims 1
208000006673 asthma Diseases 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
208000024908 graft versus host disease Diseases 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
208000004296 neuralgia Diseases 0.000 claims 1
208000021722 neuropathic pain Diseases 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1

JP2017566812A 2015-06-24 2016-06-23 ヘテロアリール置換のアミノピリジン化合物 Active JP6720225B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN1880DE2015		2015-06-24
IN1880/DEL/2015		2015-06-24
PCT/US2016/038862 WO2016210037A1 (en)	2015-06-24	2016-06-23	Heteroaryl substituted aminopyridine compounds

Publications (3)

Publication Number	Publication Date
JP2018524331A JP2018524331A (ja)	2018-08-30
JP2018524331A5 true JP2018524331A5 (2)	2019-07-18
JP6720225B2 JP6720225B2 (ja)	2020-07-08

Family

ID=56345252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017566812A Active JP6720225B2 (ja)	2015-06-24	2016-06-23	ヘテロアリール置換のアミノピリジン化合物

Country Status (9)

Country	Link
US (1)	US10202390B2 (2)
EP (1)	EP3313844B1 (2)
JP (1)	JP6720225B2 (2)
CN (1)	CN108026099B (2)
AR (1)	AR105114A1 (2)
ES (1)	ES2822956T3 (2)
TW (1)	TW201713663A (2)
UY (1)	UY36747A (2)
WO (1)	WO2016210037A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016210036A1 (en) *	2015-06-24	2016-12-29	Bristol-Myers Squibb Company	Heteroaryl substituted aminopyridine compounds
TW201718571A (zh)	2015-06-24	2017-06-01	必治妥美雅史谷比公司	經雜芳基取代之胺基吡啶化合物
ES2822956T3 (es)	2015-06-24	2021-05-05	Bristol Myers Squibb Co	Compuestos de aminopiridina sustituidos con heteroarilo
TW202340194A (zh)	2017-02-16	2023-10-16	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
PE20191817A1 (es)	2017-05-11	2019-12-27	Bristol Myers Squibb Co	Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
WO2019111218A1 (en)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh)	2018-07-13	2024-05-21	美商基利科學股份有限公司	衍生物
TWI727392B (zh)	2018-08-13	2021-05-11	美商基利科學股份有限公司	噻二唑irak4抑制劑
CN112566697B (zh)	2018-08-13	2024-04-16	吉利德科学公司	作为IRAK4抑制剂的吡咯并[1,2-b]哒嗪衍生物
WO2020036830A1 (en)	2018-08-13	2020-02-20	Gilead Sciences, Inc.	Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
CN114127075B (zh) *	2019-07-18	2024-05-14	百时美施贵宝公司	可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物
EP3999508B1 (en)	2019-07-18	2023-08-30	Bristol-Myers Squibb Company	Tricyclic heteroaryl compounds useful as irak4 inhibitors
JP7573596B2 (ja) *	2019-07-23	2024-10-25	ブリストル－マイヤーズスクイブカンパニー	Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
WO2021026181A1 (en)	2019-08-06	2021-02-11	Bristol-Myers Squibb Company	Bicyclic heterocyclic compounds useful as irak4 inhibitors
ES3059914T3 (en)	2019-08-13	2026-03-24	Bristol Myers Squibb Co	Bicyclic heteroaryl compounds useful as irak4 inhibitors
EP4100408B1 (en)	2020-02-03	2024-02-28	Bristol-Myers Squibb Company	Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021158495A1 (en)	2020-02-03	2021-08-12	Bristol-Myers Squibb Company	Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
EP4107158A1 (en) *	2020-02-19	2022-12-28	Nurix Therapeutics, Inc.	Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
CN113149995A (zh) *	2021-03-31	2021-07-23	安徽驱石医药科技有限公司	一种7-氟吡唑并[1,2-b]吡嗪-4-甲腈的合成方法及应用
FI4367118T3 (fi)	2021-08-18	2025-04-09	Nurix Therapeutics Inc	Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6825190B2 (en)	2001-06-15	2004-11-30	Vertex Pharmaceuticals Incorporated	Protein kinase inhibitors and uses thereof
AUPR688101A0 (en)	2001-08-08	2001-08-30	Luminis Pty Limited	Protein domains and their ligands
GB0211019D0 (en)	2002-05-14	2002-06-26	Syngenta Ltd	Novel compounds
AU2003244098A1 (en)	2002-06-28	2004-01-19	Yamanouchi Pharmaceutical Co., Ltd.	Diaminopyrimidinecarboxa mide derivative
EP1590341B1 (en)	2003-01-17	2009-06-17	Warner-Lambert Company LLC	2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CA2531401A1 (en)	2003-07-10	2005-01-27	Neurogen Corporation	Substituted heterocyclic diarylamine analogues
GB0402653D0 (en)	2004-02-06	2004-03-10	Cyclacel Ltd	Compounds
US7521457B2 (en)	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
FR2896503B1 (fr)	2006-01-23	2012-07-13	Aventis Pharma Sa	Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2663091A1 (en) *	2006-09-07	2008-03-13	Biogen Idec Ma Inc.	Modulators of interleukin-1 receptor-associated kinase
KR20100020454A (ko)	2007-06-08	2010-02-22	바이엘 크롭사이언스 소시에떼아노님	살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
WO2009046416A1 (en)	2007-10-05	2009-04-09	Targegen Inc.	Anilinopyrimidines as jak kinase inhibitors
JPWO2010058846A1 (ja)	2008-11-21	2012-04-19	アステラス製薬株式会社	４，６−ジアミノニコチンアミド化合物
WO2010061971A1 (ja)	2008-11-28	2010-06-03	興和株式会社	ピリジン－３－カルボキシアミド誘導体
EP2440204B1 (en)	2009-06-12	2013-12-18	Bristol-Myers Squibb Company	Nicotinamide compounds useful as kinase modulators
EP2493863B1 (en)	2009-10-30	2015-02-25	Janssen Pharmaceutica NV	Phenoxy-substituted pyrimidines as opioid receptor modulators
KR20120130104A (ko)	2010-02-01	2012-11-28	닛뽕 케미파 가부시키가이샤	Ｇｐｒ119 작동약
CN103619854A (zh)	2011-04-29	2014-03-05	西奈山伊坎医学院	激酶抑制剂
WO2013106614A1 (en) *	2012-01-13	2013-07-18	Bristol-Myers Squibb Company	Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) *	2012-01-13	2017-09-08	百时美施贵宝公司	用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
EP2802576B1 (en)	2012-01-13	2018-06-27	Bristol-Myers Squibb Company	Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
KR20150079963A (ko) *	2012-11-08	2015-07-08	브리스톨-마이어스 스큅 컴퍼니	키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
US9315494B2 (en)	2012-11-08	2016-04-19	Bristol-Myers Squibb Company	Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
CN104781251B (zh)	2012-11-08	2016-12-14	百时美施贵宝公司	可作为激酶调节剂的经双环杂环取代的吡啶基化合物
AR094537A1 (es)	2013-11-07	2015-08-12	Bristol Myers Squibb Co	COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
TW201609693A (zh) *	2014-01-03	2016-03-16	必治妥美雅史谷比公司	雜芳基取代之菸鹼醯胺化合物
TW201718571A (zh)	2015-06-24	2017-06-01	必治妥美雅史谷比公司	經雜芳基取代之胺基吡啶化合物
ES2822956T3 (es)	2015-06-24	2021-05-05	Bristol Myers Squibb Co	Compuestos de aminopiridina sustituidos con heteroarilo

2016
- 2016-06-23 ES ES16734832T patent/ES2822956T3/es active Active
- 2016-06-23 EP EP16734832.5A patent/EP3313844B1/en active Active
- 2016-06-23 CN CN201680043479.4A patent/CN108026099B/zh active Active
- 2016-06-23 TW TW105119779A patent/TW201713663A/zh unknown
- 2016-06-23 WO PCT/US2016/038862 patent/WO2016210037A1/en not_active Ceased
- 2016-06-23 UY UY0001036747A patent/UY36747A/es not_active Application Discontinuation
- 2016-06-23 AR ARP160101893A patent/AR105114A1/es unknown
- 2016-06-23 US US15/738,435 patent/US10202390B2/en active Active
- 2016-06-23 JP JP2017566812A patent/JP6720225B2/ja active Active

Publication	Publication Date	Title
JP2018524331A5 (2)	2019-07-18
RU2019118623A (ru)	2020-12-21	Пирролопиримидины в качестве потенциаторов мвтр
TWI494314B (zh)	2015-08-01	５,７－取代的－咪唑并［１,２－ｃ］嘧啶
JP2018522859A5 (2)	2019-07-18
HRP20240994T1 (hr)	2024-10-25	Spoj inhibitora jak i njegova uporaba
TWI598343B (zh)	2017-09-11	非核苷反轉錄酶抑制劑
CN105143207B (zh)	2018-04-24	作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
US10023576B2 (en)	2018-07-17	Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
JP2019504821A5 (2)	2019-12-26
JP2013523884A5 (2)	2014-05-22
JP2018044008A5 (2)	2018-05-10
HRP20201746T1 (hr)	2020-12-25	Aromatski derivati sulfonamida
JP2018522046A5 (2)	2019-09-12
JP2017501202A5 (2)	2018-12-13
JP2011509937A5 (2)	2012-02-23
EP1841757A2 (en)	2007-10-10	Heteroaromatic quinoline compounds and their use as pde10 inhibitors
JP2010510319A5 (2)	2011-01-13
JP2018524331A (ja)	2018-08-30	ヘテロアリール置換のアミノピリジン化合物
JP2020523309A5 (2)	2021-07-26
EP3209664A1 (en)	2017-08-30	Bicyclic heteroaryl amine compounds as pi3k inhibitors
RU2020114670A (ru)	2021-11-12	Бициклические соединения для применения в качестве ингибиторов rip1 киназы
JPWO2021021986A5 (2)	2023-08-07
JP2013518823A5 (2)	2014-03-27
RU2018105872A (ru)	2019-09-05	Этинильные производные
JP2012508225A5 (2)	2012-12-13